428 related articles for article (PubMed ID: 27131401)
1. Neonatal Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Treatment at United States Children's Hospitals.
Slaughter JL; Stenger MR; Reagan PB; Jadcherla SR
J Pediatr; 2016 Jul; 174():63-70.e3. PubMed ID: 27131401
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
3. A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants.
Tan J; Jeffries S; Carr R
Paediatr Drugs; 2023 Sep; 25(5):557-576. PubMed ID: 37458926
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Histamine
Hammond DA; Kathe N; Shah A; Martin BC
Pharmacotherapy; 2017 Jan; 37(1):43-53. PubMed ID: 27809338
[TBL] [Abstract][Full Text] [Related]
5. Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study.
Ruigómez A; Johansson S; Nagy P; García Rodríguez LA
Curr Med Res Opin; 2017 Dec; 33(12):2201-2209. PubMed ID: 28699796
[TBL] [Abstract][Full Text] [Related]
6. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
MacLaren R; Reynolds PM; Allen RR
JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
[TBL] [Abstract][Full Text] [Related]
7. Anti-reflux medication use in preterm infants.
Binti Abdul Hamid H; Szatkowski L; Budge H; Ojha S
Pediatr Res; 2022 Aug; 92(2):520-525. PubMed ID: 34716422
[TBL] [Abstract][Full Text] [Related]
8. Early Acid Suppression Therapy Exposure and Fracture in Young Children.
Malchodi L; Wagner K; Susi A; Gorman G; Hisle-Gorman E
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31175146
[TBL] [Abstract][Full Text] [Related]
9. Effects of daily treatment with acid suppressants for stress ulcer prophylaxis on risk of ventilator-associated events.
Li X; Klompas M; Menchaca JT; Young JG
Infect Control Hosp Epidemiol; 2020 Feb; 41(2):187-193. PubMed ID: 31818336
[TBL] [Abstract][Full Text] [Related]
10. Gastric Acid Suppressant Prophylaxis in Pediatric Intensive Care: Current Practice as Reflected in a Large Administrative Database.
Costarino AT; Dai D; Feng R; Feudtner C; Guevara JP
Pediatr Crit Care Med; 2015 Sep; 16(7):605-12. PubMed ID: 25901549
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
Barkun AN; Adam V; Martel M; Bardou M
Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
[TBL] [Abstract][Full Text] [Related]
12. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
[TBL] [Abstract][Full Text] [Related]
13. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
14. A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients.
Fleishman NR; Richardson T; Attard TM
Curr Med Res Opin; 2022 Apr; 38(4):565-570. PubMed ID: 35112645
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
16. A pragmatic assessment of proton pump inhibitors vs. histamine type 2 receptor antagonists on clinically important gastrointestinal bleeding and mortality when used for stress ulcer prophylaxis in the ICU.
Boyd C; Hassig T; MacLaren R
Pharmacotherapy; 2021 Oct; 41(10):820-827. PubMed ID: 34478588
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.
McCaleb RV; Gandhi AS; Clark SM; Clemmons AB
Ann Pharmacother; 2016 Jul; 50(7):541-7. PubMed ID: 27091869
[TBL] [Abstract][Full Text] [Related]
18. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
19. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
